Medigen Biotechnology (3176) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medigen Biotechnology (3176) has a cash flow conversion efficiency ratio of -0.004x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-18.91 Million ≈ $-595.86K USD) by net assets (NT$4.90 Billion ≈ $154.29 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medigen Biotechnology - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Medigen Biotechnology's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Medigen Biotechnology for a breakdown of total debt and financial obligations.
Medigen Biotechnology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medigen Biotechnology ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NCC AB (publ)
ST:NCC-A
|
0.250x |
|
Domo Inc
NASDAQ:DOMO
|
-0.018x |
|
Heran Co Ltd
TW:5283
|
0.153x |
|
NevGold Corp
V:NAU
|
0.003x |
|
Insas Bhd
KLSE:3379
|
-0.007x |
|
Carbios
PA:ALCRB
|
-0.090x |
|
PRL Global Ltd
AU:PRG
|
0.079x |
|
INKEVERSE GROUP DL-001
F:5IK
|
N/A |
Annual Cash Flow Conversion Efficiency for Medigen Biotechnology (2003–2024)
The table below shows the annual cash flow conversion efficiency of Medigen Biotechnology from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see Medigen Biotechnology market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$5.04 Billion ≈ $158.73 Million |
NT$37.92 Million ≈ $1.19 Million |
0.008x | +106.61% |
| 2023-12-31 | NT$5.00 Billion ≈ $157.44 Million |
NT$-569.40 Million ≈ $-17.94 Million |
-0.114x | +34.61% |
| 2022-12-31 | NT$6.47 Billion ≈ $203.87 Million |
NT$-1.13 Billion ≈ $-35.53 Million |
-0.174x | -316.41% |
| 2021-12-31 | NT$6.43 Billion ≈ $202.46 Million |
NT$517.45 Million ≈ $16.30 Million |
0.081x | +153.97% |
| 2020-12-31 | NT$4.50 Billion ≈ $141.76 Million |
NT$-671.38 Million ≈ $-21.15 Million |
-0.149x | +28.47% |
| 2019-12-31 | NT$2.69 Billion ≈ $84.60 Million |
NT$-560.17 Million ≈ $-17.65 Million |
-0.209x | -15.80% |
| 2018-12-31 | NT$2.94 Billion ≈ $92.66 Million |
NT$-529.82 Million ≈ $-16.69 Million |
-0.180x | -25.74% |
| 2017-12-31 | NT$3.18 Billion ≈ $100.19 Million |
NT$-455.62 Million ≈ $-14.35 Million |
-0.143x | -8.16% |
| 2016-12-31 | NT$3.54 Billion ≈ $111.46 Million |
NT$-468.61 Million ≈ $-14.76 Million |
-0.132x | -255.98% |
| 2015-12-31 | NT$3.46 Billion ≈ $109.14 Million |
NT$294.18 Million ≈ $9.27 Million |
0.085x | -31.58% |
| 2005-12-31 | NT$650.39 Million ≈ $20.49 Million |
NT$80.72 Million ≈ $2.54 Million |
0.124x | -76.13% |
| 2003-12-31 | NT$856.65 Million ≈ $26.99 Million |
NT$445.46 Million ≈ $14.03 Million |
0.520x | -- |
About Medigen Biotechnology
Medigen Biotechnology Corp., a biopharmaceutical company, engages in the research and development of new drugs and vaccines, cell therapy, advanced nucleic acid testing, generic drugs, medical beauty, and vaccine-related products in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has complete… Read more